Summary
Seventy-four patients in 1978 and 316 in 1986, all transfused during open-heart surgery in Stockholm, Sweden, were studied prospectively for the development of posttransfusion non-A, non-B (NANB) hepatitis, seroconversion to hepatitis C virus antibodies (anti-HCV) (C-100), time lag to seroconversion to anti-HCV and outcome of posttransfusion NANB/C hepatitis. Anti-HCV was tested up to six months after transfusions in patients from 1978 and up to one year after transfusions in patients from 1986. Fifty-four percent of the patients who developed posttransfusion NANB hepatitis seroconverted to anti-HCV, 7/15 (47%) in 1978 and 8/13 (62%) in 1986. Four (27%) of the 15 patients who seroconverted to anti-HCV were anti-HCV reactive within one week, 12 (80%) within eight weeks and all within 18 weeks after the onset of hepatitis. The ELISA optical density/cut-off (OD/CO) ratio was above 4.0 in all patients with hepatitis C who seroconverted. One transfused patient with normal serum aminotransferase levels throughout follow-up seroconverted after six months. He had a temporary positive anti-HCV reactivity with a maximal ELISA OD/CO ratio for anti-HCV of only 1.2, which became negative three years later. Development of chronic hepatitis was noticed in 9/15 (60%) patients who seroconverted to anti-HCV and in 5/13 (38%) patients with posttransfusion NANB hepatitis who did not seroconvert.
Zusammenfassung
74 Patienten, die 1978, und 316 Patienten, die 1986 während offener Herzchirurgie in Stockholm, Schweden, Transfusionen erhielten, wurden in eine prospektive Studie aufgenommen und im Hinblick auf das Auftreten einer Non-A, Non-B-Posttransfusions-hepatitis, Serokonversion für Hepatitis C Virus-Antikörper (anti-HCV, C-100), Zeitspanne bis zur Serokonversion für anti-HCV und Verlauf der NANB/C-Posttransfusionshepatitis untersucht. Bei Patienten, die 1978 transfundiert worden waren, wurden Untersuchungen auf anti-HCV bis zu sechs Monate nach der Transfusion und bei 1986 Transfundierten bis zu einem Jahr nach Transfusion durchgeführt. Eine Serokonversion zu anti-HCV trat bei 54% der Patienten mit NANB-Posttransfusions-hepatitis ein, 7/15 (47%) der Patienten aus dem Jahr 1978 und 8/13 (62%) aus dem Jahr 1986. Die Serokonversion zu anti-HCV trat bei vier der 15 Patienten (27%) schon innerhalb einer Woche ein, bei 12 (80%) innerhalb acht Wochen und bei allen innerhalb 18 Wochen nach Beginn der Hepatitis. Bei den Patienten mit Hepatitis C, die eine Serokonversion entwickelten, lag der Quotient von ELISA Meßwert zu Grenzwert (Optical density/ Cut-off, OD/CO) in allen Fällen über 4,0. Ein Patient, bei dem nach der Transfusion stets normale Serum- Aminotransferase-Spiegel vorlagen, zeigte nach sechs Monaten eine Serokonversion. Er war vorübergehend anti-HCV positiv, der ELISA OD/CO- Quotient für anti-HCV betrug maximal 1,2; nach drei Jahren war er seronegativ. Bei neun der 15 Patienten (60%) war eine chronische Hepatitis nach Serokonversion für anti-HCV zu beobachten. Unter den 13 Patienten mit NANB-Posttransfusionshepatitis, die keine Serokonversion zeigten, entwickelten fünf eine chronische Hepatitis (38%).
Similar content being viewed by others
References
Kuo, G., Choo, Q. L., Alter, H. J., Gitnick, G. L., Redeker, A. G., Purcell, R. H., Miyamura, T., Dienstag, J. L., Alter, M. J., Stevens, C. E., Tegtmeier, G. E., Bonino, F., Colombo, M., Lee, W. S., Kuo, C., Berger, K., Shuster, J. R., Overby, L. R., Bradley, D. W., Houghton, M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244 (1989) 362–364.
Alter, H. J., Purcell, R. H., Shih, J. W., Melpolder, J. C., Houghton, M., Choo, Q. L., Kuo, G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321 (1989) 1494–1500.
van der Poel, C. L., Reesink, H. W., Schaasberg, W., Leentvaar-Kuypers, A., Bakker, E., Exel-Oehlers, P. J., Lelie, P. N. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet i (1990) 558–560.
Esteban, J. I., Viladomiu, L., Gonzaléz, A., Roget, M., Genesca, J., Esteban, R., López-Talavera, J. C., Hernández, J. M., Vargas, V., Buti, M., Guardia, J., Houghton, M., Choo, Q. L., Kuo, G. Hepatitis C virus antibodies among risk groups in Spain. Lancet ii (1989) 294–297.
Grillner, L., Bergdahl, S., Jyrälä, A. Non-A, Non-B hepatitis after open-heart surgery in Sweden. Scand. J. Infect. Dis. 14 (1982) 171–175.
Mattsson, L., Åberg, B., Weiland, O., Sellman, M., Davilén, J. Non-A, non-B hepatitis after open-heart surgery in Stockholm: declining incidence after introduction of restrictions for blood donations due to the human immunodeficiency virus. Scand. J. Infect. Dis. 20 (1988) 371–376.
Siegel, S., Castellan Jr., N. Nonparametric statistics for the behavioral sciences. McGraw-Hill Book Co., New York 1988, pp. 339–346.
Esteban, J. I., González, A., Hernández, J. M., Viladomiu, L., Sánchez, C., López-Talavera, J. C., Lucea, D., Martin-Vega, C., Vidal, X., Esteban, R., Guardia, J. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N. Engl. J. Med. 323 (1990) 1107–1112.
Krogsgaard, K., Wantzin, P., Mathiesen, L. R., Sonne, J., Ring-Larsen, H., The Copenhagen Hepatitis Acuta Programme Early appearance of antibodies to hepatitis C virus in community acquired acute non-A, non-B hepatitis is associated with progression to chronic liver disease. Scand. J. Infect. Dis. 22 (1990) 399–402.
van der Poel, C. L., Reesink, H. W., Lelie, P. N., Leentvaar-Kuypers, A., Choo, Q. L., Kuo, G., Houghton, M. Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in the Netherlands. Lancet ii (1989) 297–298.
van der Poel, C. L., Reesink, H. W., Lelie, P. N., Exel-Oehlers, P., Winkel, I., Schaasberg, W., Polito, A., Houghton, M. Anti-HCV and transaminase testing of blood donors. Lancet ii (1990) 187–188.
Tanaka, E., Kiyosawa, K., Sodeyama, T., Nakano, Y., Shimizu, S., Seki, T., Furuta, S., Kameko, M. Anti-HCV and long-term prognosis in patients with non-A, non-B post-transfusion hepatitis. Jpn. J. Gastroenterol. 87 (1990) 1003–1009.
Mosley, J. W., Aach, R. D., Hollinger, F. B., Stevens, C. E., Barbosa, L. H., Nemo, G. J., Holland, P. V., Bancroft, W. H., Zimmermann, H. J., Kuo, G., Choo, Q. L., Houghton, M. Non-A, non-B hepatitis and antibody to hepatitis C virus. JAMA 263 (1990) 77–78.
Weiner, A. J., Kuo, G., Bradley, D. W., Bonino, F., Saracco, G., Lee, C., Rosenblatt, J., Choo, Q. L., Houghton, M. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet i (1990) 1–3.
Bradley, D. W., Maynard, J. E., Popper, H., Cook, E. H., Ebert, J. W., McCaustland, K. A., Schable, C. A., Fields, H. A. Posttransfusion non-A, non-B hepatitis: physiochemical properties of two distinct agents. J. Infect. Dis. 148 (1983) 254–265.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mattsson, L., Bergdahl, S., Weiland, O. et al. Seroconversion to hepatitis C virus antibodies in patients with acute posttransfusion non-A, non-B hepatitis in Sweden. Infection 19, 309–312 (1991). https://doi.org/10.1007/BF01645353
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01645353